Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Sonoma Pharmaceuticals Inc

SNOA ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: N/A

Last Close

$1.10

▼ -5.98%

Market Cap $5.27M · Vol 29.51K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$5.27M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

29.03

Momentum

Beta

1.30

vs Market

52W High

$3.97

72.29% below

52W Low

$0.85

29.40% above

Volume

29.51K

Avg 11.46K

P/B

1.24

Price-to-book

ROE

N/A

Return on equity

Free Float

99.58%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Sonoma Pharmaceuticals Inc (SNOA) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SNOA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.65%

-14.06%

-2.65%

+0.00%

YTD

-69.78%

-72.01%

-66.36%

-99.05%

Financials & Valuation

TTM · Annual

Total Revenue	$19.53M
Net Income	$-3,175,000.00
Revenue Growth (YoY)	+59.55%
Gross Margin	37.97%
Operating Margin	-12.60%
Net Profit Margin	-16.26%
ROE	N/A
ROA · ROIC	-24.73% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	0.18
P/B	1.24
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	4.79M

Technical Indicators

50-Day SMA	$1.24
200-Day SMA	$1.70
RSI (14)	29.03
Beta	1.30
52-Week High	$3.97
52-Week Low	$0.85

Volume Today	29.51K
Avg Daily Volume (30D)	11.46K
Relative Volume	2.57x
Volatility (10D)	39.23
Volatility (30D)	42.49
Free Float	99.58%

Analyst Consensus

N/A

Current Price $1.10

Mean Target N/A

52W Low$0.85 52W High$3.97

Current

Target

$0.85 $3.97

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001SQ8K88

ISINUS83558L3033

CountryUSA

Sub-IndustryPharmaceuticals (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Company +3.19% JNJ Johnson & Johnson -0.73% ABBV AbbVie Inc. +1.41% NVS Novartis AG -0.19% NOVN.S Novartis AG +1.12%

Company Profile

Sonoma Pharmaceuticals, Inc. is a global healthcare company. The Company is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. It offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.